YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$14.84 USD
-0.45 (-2.94%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.83 -0.01 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
YMAB 14.84 -0.45(-2.94%)
Will YMAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
New Strong Buy Stocks for April 19th
New Strong Buy Stocks for April 17th
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
Other News for YMAB
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Y-mAbs Therapeutics says CFO Kruse will resign from his role
Y-mAbs Therapeutics CFO Bo Kruse resigns